| Phase 1 | 1 | |
| Phase 1/2 | 1 | |
| Phase 2 | 1 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07678229 | BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in… | Extranodal NK/T-cell Lymphoma | Recruiting | 2026-08-13 |
| Phase 2 | ||||
| NCT07507318 | Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission | Diffuse Large B-Cell Lymphoma | Recruiting | 2026-06-18 |
| Phase 1/2 | ||||
| NCT07502768 | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Recruiting | 2026-06-18 |
| Phase 1 | ||||
| NCT06445803 | CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL | Acute Lymphoblastic Leukemia, in Relapse | Recruiting | 2024-06-06 |
| Not specified | ||||
| NCT07727083 | Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative… | Extranodal NK/T-cell Lymphoma | Recruiting | 2026-08-13 |
Non-Hodgkin Lymphoma (5) · Leukemia (2) · Acute Lymphoblastic Leukemia (ALL) (1) · DLBCL (1)